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Selective internal radiation therapy (SIRT), also termed
radioembolisation, is a form of brachytherapy that was
developed to improve local control of either primary
or secondary malignancies within the liver. High-
dose radiation, delivered via the hepatic artery using
yttrium-90 (90Y)-labeled resin or glass microspheres,
allows the treatment of multiple sites of disease in the
liver in a single procedure.
SIRT is now recognised as part of the modern
treatment paradigm for the management of unresectable
advanced hepatocellular and liver-dominant metastatic
colorectal cancers. A number of other cancers with
similar radiobiological proﬁles, including breast cancer,
melanoma and pancreatic cancer, are being studied as
candidates for SIRT. The aim of this short article is
to discuss the evidence for the effectiveness of this
procedure in the treatment of liver tumours of various
primary tumour origins, with an emphasis on the
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treatment of liver-dominant breast cancer, melanoma
and pancreatic cancer.
1. Metastatic breast cancer
Approximately one in ﬁve patients with breast cancer de-
velop advancedmetastatic disease − three-quarters (15%)
after prior treatment and the remainder (5%) initially
present with advanced disease. 1 Of those with advanced
breast cancer, approximately one-third will present with
liver metastases (either as the sole site [6−8%] or in
combination with at least one other site of disease
[26% of patients]). 2−4 Survival for patients with advanced
disease is approximately 2 years, 5 but varies widely
according to the hormone receptor status, rate of
recurrence and site of disease spread. 6 Patients with
visceral disease have the poorest outlook − often with
a short interval before recurrence − and tend to be
associated with biologically more aggressive forms of
breast cancer. 7 Median survival in patients with newly
diagnosed liver metastases ranges between 14.5 and
16.0 months. 3,6
To date there are 3 published studies of SIRT
monotherapy (but none in combination with chemo-
therapy). All patients in these studies had unresectable
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liver metastases from breast cancer and included some
with limited extrahepatic disease − bone or lymph nodal
metastases but not brain metastases. 8−10
Coldwell and colleagues evaluated 44 patients with
symptomatic bilateral hepatic lesions. All patients had
received prior doxorubicin and docetaxel therapy; and
32 (73%) had failed 3 or more lines of chemotherapy. 8 The
remaining 12 (27%) received SIRT for liver progression
during a treatment hiatus between ﬁrst- and second-
line chemotherapy. At 14 months median follow-up,
92% (11 of 12) of the patients who were treated
during a treatment hiatus after ﬁrst-line or second-line
chemotherapy were still alive, and 84% (27 of 32) of
the chemorefractory patients remained alive. Grade 3
toxicities (nausea, vomiting, and pain) occurred in
7 patients (16%).
In a second prospective evaluation of 30 patients with
chemorefractory disease, median overall survival was
11.7 months with a longer survival among responders
compared with non-responders (23.6 vs. 5.7 months;
P = 0.005) and in patients with liver-only disease com-
pared with those with extrahepatic disease (16 vs.
9.6 months; P = 0.077). 9 Three patients were sufﬁciently
downsized for potentially curative radiofrequency abla-
tion, which was performed successfully with complete
ablation of the residual tumour. 11 Clinically signiﬁcant
toxicities following SIRT included: nausea and vomiting,
gastric ulcers, and increasing transaminase and bilirubin
levels and ascites, which occurred in 8 of the 30
patients. One patient died due to treatment-related
hepatic toxicity at day 90. 9
A third phase II open-label study was conducted
in 27 patients who had received 3 to 6 lines of
chemotherapy as well as liver-directed therapy com-
prising: RFA (n=1), hepatic resection (n=1), or chemo-
embolisation (n=1). 10 Median survival varied by perfor-
mance status: 6.8 months compared with 2.6 months
(P = 0.24) in patients with Eastern Cooperative Oncology
Group (ECOG) performance status 0 (n=15) versus
ECOG 1, 2, or 3 (n=12), respectively; and by tumour
burden in the liver: 9.4 months versus 2.0 months
(P< 0.0001) in patients with tumour affecting <25% ver-
sus25% of the liver volume. 10 Three patients developed
grade 3 bilirubin toxicity, 1 had biliary obstruction on
imaging, 1 had haemorrhagic necrosis of the left hepatic
lobe with clinical sequelae, and another required a
cholecystectomy due to radiation-induced cholecystitis.
2. Ocular melanoma
Systemic metastases develop in approximately half of
patients with primary uveal melanoma, with the liver
the predominant organ involved in 70−90% of cases. 12,13
Survival after the development of liver metastases is
poor, ranging from a median of 2 to 9 months. 13 Only
a few patients with hepatic metastases are surgical can-
didates because of the frequent presentation of multiple
tumours in both lobes of the liver. Beyond conventional
TACE, a number of novel locoregional treatments are
being evaluated in clinical trials, including: doxorubicin-
eluting beads, immunoembolisation with granulocyte–
macrophage colony-stimulating factor (GM-CSF), SIRT
with 90Y resin microspheres and percutaneous hepatic
perfusion (PHP) with melphalan. 13
Median survival with SIRT in highly pretreated
patients with metastatic melanoma is approximately
10 months, 14,15 and compares favourably with conven-
tional TACE. 14,15 Consistent with the experience with all
other locoregional therapies, survival was signiﬁcantly
diminished in patients with a large pretreatment
tumour burden. 14 Patients with more than 25% replace-
ment of liver volume by tumour had a signiﬁcantly
shorter median survival (3.9 vs 10.5 months, p=0.0003)
than patients with less than 25% tumour burden. 14 Early
evidence from two case series indicates that SIRT was
generally well tolerated except for one grade 3 event of a
gastric ulcer that healed uneventfully within 6 weeks of
supportive care. 14,16
3. Pancreatic cancer
Metastastic disease in the liver occurs in 80−95% of
patients with pancreatic adenocarcinomas, and is often
present at the time of diagnosis. Modern systemic
chemotherapy with FOLFIRINOX is associated with a
median survival of approximately 11 months, which
is a marked improvement over gemcitabine. 17 In the
era before the treatment of patients with FOLFIRINOX,
patients who were refractory to gemcitabine treatment
had a median survival of 5−6 months after SIRT; 18,19
although patient numbers were low and the incidence
of grade 3 events varied markedly between each case
series. 18−21
4. Conclusions
Provisional evidence, mostly from retrospective case
series, indicates the potential of SIRT in improving the
control of liver metastases of various tumor origins.
Treatment is equally effective in both hypervascular and
hypovascular tumours. 22 Prospective clinical studies are
needed to evaluate the relative effectiveness of combin-
ing conventional chemotherapy with and without SIRT.
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